A study of Oral CR845 in non-dialysis chronic kidney disease (CKD) associated pruritus population.
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2017
Price : $35 *
At a glance
- Drugs Difelikefalin (Primary)
- Indications Pruritus
- Focus Adverse reactions
- 25 Oct 2017 According to a Cara Therapeutics media release, first patient has been dosed in the study.
- 25 Oct 2017 Status changed from planning to recruiting, according to a Cara Therapeutics media release.
- 03 Aug 2017 According to a Cara Therapeutics media release, the company expects to initiate this trial in the fourth quarter of 2017.